Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase 2 study.
Naoya KatoMasatoshi KudoKaoru TsuchiyaAtsushi HagiharaKazushi NumataHiroshi AikataYoshitaka InabaShunsuke KondoKenta MotomuraNaohiro OkanoMasafumi IkedaManabu MorimotoShingo KurodaAkiko KimuraPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2023)
Cabozantinib showed efficacy and a manageable safety profile in Japanese patients with advanced HCC. This article is protected by copyright. All rights reserved.